US vaccine maker Novavax said on Tuesday that its COVID-19 vaccine in India, Covovax, has received emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years. The authorization is a global first for the age group for the vaccine, which is manufactured and marketed in India by Serum Institute of India. Novavax had last month announced that its vaccine was 80 percent effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.